UBS increased its price target for 10x Genomics, Inc. to $68.
The new valuation represents a significant rise from the previous $20 target. The firm maintained a Neutral rating on the life sciences technology company. Shares of 10x Genomics are currently trading near their 52-week high.
The company reported second-quarter 2026 financial results that surpassed analyst estimates. Quarterly revenue reached $151.04 million. The adjusted loss per share was $0.14. This result outperformed the forecasted loss of $0.24 per share.